Chimeric Therapeutics Ltd accelerates development of CAR T therapy as it looks to boost pipeline with additional therapies

Chimeric Therapeutics Ltd (ASX:CHM) is rapidly accelerating the development of its chlorotoxin CAR T therapy (CLTX CAR T) cell therapy as it looks for additional therapies to bring into its pipeline. 
The clinical-stage biotech company is looking at more curative therapies for patients with cancer, and not just therapies that delay disease progression. 
Chimeric Therapeutics chief operating officer Jennifer Chow said: “The company is now focused on its pipeline because we do believe that by building out a bigger pipeline or a stronger pipeline with additional assets that have the same type of promise to patients, we're actually going to be able to help more patients in the long term.”

Related Keywords

China ,United States ,American ,Jennifer Chow ,National Cancer Institute ,International Agency For Research On Cancer ,American Society Of Clinical Oncology ,Drug Administration ,American Society ,Clinical Oncology ,International Agency ,Deep Dive ,Insight ,Small Caps ,Harma Biotech ,Chimeric Therapeutics Ltd ,Asx Chm ,Roactiveinvestors ,சீனா ,ஒன்றுபட்டது மாநிலங்களில் ,அமெரிக்கன் ,ஜெனிபர் சோவ் ,தேசிய புற்றுநோய் நிறுவனம் ,அமெரிக்கன் சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல் ,அமெரிக்கன் சமூகம் ,மருத்துவ புற்றுநோயியல் ,ஆழமான டைவ் ,